PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsMecasermin
Increlex(mecasermin)
Increlex (mecasermin) is a protein pharmaceutical. Mecasermin was first approved as Increlex on 2005-08-30. It has been approved in Europe to treat laron syndrome. The pharmaceutical is active against insulin-like growth factor 1; insulin-like growth factor I. In addition, it is known to target insulin-like growth factor 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
hereditary congenital and neonatal diseases and abnormalitiesD009358
endocrine system diseasesD004700
Trade Name
FDA
EMA
Increlex
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Mecasermin
Tradename
Proper name
Company
Number
Date
Products
IncrelexmecaserminIpsenN-21839 RX2005-08-30
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
hucord hscm-100 ampouleunapproved drug other2019-12-23
increlexBiologic Licensing Application2025-05-07
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
mecasermin, Increlex, Ipsen Biopharmaceuticals, Inc.
2112-08-30Orphan excl.
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
H01: Pituitary and hypothalamic hormones and analogues
H01A: Anterior pituitary lobe hormones and analogues
H01AC: Somatropin and somatropin agonists
H01AC03: Mecasermin
H01AC05: Mecasermin rinfabate
HCPCS
Code
Description
J2170
Injection, mecasermin, 1 mg
Clinical
Clinical Trials
323 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DwarfismD004392E34.3122115
AcromegalyD00017211114
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Growth disordersD006130133
SyndromeD0135771112
Failure to thriveD00518322
Laron syndromeD046150Orphanet_633E34.321111
Chronic renal insufficiencyD051436N1811
Renal insufficiencyD051437N1911
Pituitary diseasesD010900E23.711
Turner syndromeD014424Orphanet_881Q9611
Gonadal dysgenesisD00605911
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Duchenne muscular dystrophyD020388EFO_0000429111
Muscular dystrophiesD009136EFO_0000757G71.0111
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sleep apnea syndromesD012891EFO_0003877G47.311
ApneaD001049R06.8111
Igg deficiencyD017099D80.311
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMecasermin
INNmecasermin
Description
Mecasermin (INN) (brand name Increlex), also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).
Classification
Protein
Drug classgrowth factors: insulin-like growth factors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL1201716
ChEBI ID
PubChem CID
DrugBankDB01277
UNII ID7GR9I2683O (ChemIDplus, GSRS)
Target
Agency Approved
IGF1
IGF1
Organism
Homo sapiens
Gene name
IGF1
Gene synonyms
IBP1
NCBI Gene ID
Protein name
insulin-like growth factor I
Protein synonyms
insulin-like growth factor 1 (somatomedin C), insulin-like growth factor IB, Mechano growth factor, MGF, Somatomedin-C
Uniprot ID
Mouse ortholog
Igf1 (16000)
insulin-like growth factor I (Q8C4U6)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
£
Increlex Eton Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,195 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
920 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use